BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Don't Add Extra Variables; Verify with Bio-Synthesis Cell Line Identification


12/20/2010 10:50:01 AM

LEWISVILLE, TX., Dec. 13, 2010 – Bio-Synthesis is pleased to announce a new human cell line authentication service (called "tissue authentication" or "tissue validation" in oncology) for laboratories working with HeLa, cancer cell and other cell lines.

Cell line contamination has interfered with scientific studies for years, but only recently has it come to the community's attention. In 2007, the NCI/ADR-RES breast cancer cell line was found to be contaminated with OVCAR-8, sparking the retraction of over 300 academic papers and compromising years of work. Only months later, the NIH called for all grant applicants to address the threat of cross-contamination with cell line identification measures. Increasing numbers of journals, notably Biotechniques, Cancer Research, and In Vitro Cellular and Developmental Biology now require authentication on all cell lines used in studies submitted for publication. The FDA is even more strict, requiring cell line authentication as a condition for drug approval.

Over the years, several different teams of researchers have noted the failure of phenotype and provenance to provide reliable information:

- Of 1211 cell lines published between 1989 and 2007, 23 percent were found to have discrepancies in p53 status (Berglind et al).

- Of 40 ostensibly thyroid cancer cell lines, 17 were found to lack unique genetic profiles, and some were confirmed as having come from colon cancer or melanoma sources (Schwepp et al).

- Among hematopoetic cell lines, 14.8 percent were found to be contaminated with other hematopoetic cell lines (Drexler et al).

Bio-Synthesis employs short tandem repeat analysis, the technique most highly recommended by the ATCC SDO, to confirm the identities of clients submitted samples. Standard cell line authentication services start as low as $95 for a profile of preextracted DNA. Complete cell line identification packages, however, include not only AmpFlSTR Identifiler profiling but PowerPlex 1.2, StemElite, and High-Resolution Luminex HLA DNA Genotyping. In-depth services include comparison of the client's cell line to a known sample, blind analysis of the client's cell line without any preexisting knowledge of its purported origin, comparison of the client's sample to a DNA database and and cross-contamination detection covering nine species.

Bio-Synthesis' accredited cell line testing facilities have been the home of many successful projects. Bio-Synthesis invites readers to visit www.BioSyn.com for more details on this and other services.

Spanning Across Genomics, Proteomics, and Cell Biology.

© 2010 BIO-SYNTHESIS, INC. All rights reserved

For further information, please contact:

Heidi Fazelli, [Sales Director]

Bio-Synthesis Incorporated

(800) 227-0627



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES